Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis
Authors:
Open Access
- 7 May 2020
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 21 (1) , 1-14
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a rapidly progressing disease with challenging management. To find novel effective therapies, better preclinical models are needed for the screening of anti-fibrotic compounds. Activated fibroblasts drive fibrogenesis and are the main cells responsible for the accumulation of extracellular matrix (ECM). Here, a prolonged Scar-in-a-Jar assay was combined with clinically validated biochemical markers of ECM synthesis to evaluate ECM synthesis over time. To validate the model as a drug screening tool for novel anti-fibrotic compounds, two approved compounds for IPF, nintedanib and pirfenidone, and a compound in development, omipalisib, were tested. Methods: Primary human lung fibroblasts from healthy donors were cultured for 12 days in the presence of ficoll and were stimulated with TGF-β1 with or without treatment with an ALK5/TGF-β1 receptor kinase inhibitor (ALK5i), nintedanib, pirfenidone or the mTOR/PI3K inhibitor omipalisib (GSK2126458). Biomarkers of ECM synthesis were evaluated over time in cell supernatants using ELISAs to assess type I, III, IV, V and VI collagen formation (PRO-C1, PRO-C3, PRO-C4, PRO-C5, PRO-C6), fibronectin (FBN-C) deposition and α-smooth muscle actin (α-SMA) expression. Results: TGF-β1 induced synthesis of PRO-C1, PRO-C6 and FBN-C as compared with unstimulated fibroblasts at all timepoints, while PRO-C3 and α-SMA levels were not elevated until day 8. Elevated biomarkers were reduced by suppressing TGF-β1 signalling with ALK5i. Nintedanib and omipalisib were able to reduce all biomarkers induced by TGF-β1 in a concentration dependent manner, while pirfenidone had no effect on α-SMA. Conclusions: TGF-β1 stimulated synthesis of type I, III and VI collagen, fibronectin and α-SMA but not type IV or V collagen. Synthesis was increased over time, although temporal profiles differed, and was modulated pharmacologically by ALK5i, nintedanib, pirfenidone and omipalisib. This prolonged 12-day Scar-in-a-Jar assay utilising biochemical markers of ECM synthesis provides a useful screening tool for novel anti-fibrotic compounds.Keywords
Funding Information
- The Danish Agency for Science, Technology and Innovation
This publication has 58 references indexed in Scilit:
- Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cellsBMC Pulmonary Medicine, 2012
- Serological Investigation of the Collagen Degradation Profile of Patients with Chronic Obstructive Pulmonary Disease or Idiopathic Pulmonary FibrosisBiomarker Insights, 2012
- Integrating mechanisms of pulmonary fibrosisJournal of Experimental Medicine, 2011
- Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosisBiomarkers, 2011
- Clinical and histopathological evaluation of collagen fiber orientation in patients with oral submucous fibrosisJournal of Oral and Maxillofacial Pathology, 2011
- Novel therapeutic approaches for pulmonary fibrosisBritish Journal of Pharmacology, 2011
- Diminished Prostaglandin E2 Contributes to the Apoptosis Paradox in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- The Scar‐in‐a‐Jar: studying potential antifibrotic compounds from the epigenetic to extracellular level in a single wellBritish Journal of Pharmacology, 2009
- Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated human lung fibroblastsLife Sciences, 2008
- In Vitro Enhancement of Collagen Matrix Formation and Crosslinking for Applications in Tissue Engineering: A Preliminary StudyTissue Engineering, 2007